Uncategorized

New biotech cAMPfield emerges with $180M to reshape IBD treatment

Published

4 hours ago

on

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version